<?xml version='1.0' encoding='utf-8'?>
<document id="15385831"><sentence text="Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man."><entity charOffset="11-24" id="DDI-PubMed.15385831.s1.e0" text="ciprofloxacin" /><entity charOffset="63-73" id="DDI-PubMed.15385831.s1.e1" text="mexiletine" /><pair ddi="false" e1="DDI-PubMed.15385831.s1.e0" e2="DDI-PubMed.15385831.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15385831.s1.e0" e2="DDI-PubMed.15385831.s1.e1" /></sentence><sentence text="Mexiletine is extensively metabolized in man, with less than 10% of the dose being excreted unchanged in urine"><entity charOffset="0-10" id="DDI-PubMed.15385831.s2.e0" text="Mexiletine" /></sentence><sentence text=" Clinical drug-drug interaction studies as well as in vitro drug metabolism studies suggest that CYP1A2, in addition to CYP2D6, is involved in the metabolism of mexiletine in man"><entity charOffset="161-171" id="DDI-PubMed.15385831.s3.e0" text="mexiletine" /></sentence><sentence text=" Therefore, the objective of the study was to determine whether potential inhibition of CYP1A2 by the quinolone antibiotic agent ciprofloxacin would alter the stereoselective disposition of mexiletine"><entity charOffset="102-111" id="DDI-PubMed.15385831.s4.e0" text="quinolone" /><entity charOffset="129-142" id="DDI-PubMed.15385831.s4.e1" text="ciprofloxacin" /><entity charOffset="190-200" id="DDI-PubMed.15385831.s4.e2" text="mexiletine" /><pair ddi="false" e1="DDI-PubMed.15385831.s4.e0" e2="DDI-PubMed.15385831.s4.e0" /><pair ddi="false" e1="DDI-PubMed.15385831.s4.e0" e2="DDI-PubMed.15385831.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15385831.s4.e0" e2="DDI-PubMed.15385831.s4.e2" /><pair ddi="false" e1="DDI-PubMed.15385831.s4.e1" e2="DDI-PubMed.15385831.s4.e1" /><pair ddi="false" e1="DDI-PubMed.15385831.s4.e1" e2="DDI-PubMed.15385831.s4.e2" /></sentence><sentence text=" Nineteen healthy men (10 smokers and 9 nonsmokers) received a single 200-mg oral dose of racemic mexiletine hydrochloride on 2 occasions: once alone and once during concomitant administration of ciprofloxacin 750 mg BID (starting 3 days before and up to 2 days after the administration of mexiletine)"><entity charOffset="90-122" id="DDI-PubMed.15385831.s5.e0" text="racemic mexiletine hydrochloride" /><entity charOffset="196-209" id="DDI-PubMed.15385831.s5.e1" text="ciprofloxacin" /><entity charOffset="290-300" id="DDI-PubMed.15385831.s5.e2" text="mexiletine" /><pair ddi="false" e1="DDI-PubMed.15385831.s5.e0" e2="DDI-PubMed.15385831.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15385831.s5.e0" e2="DDI-PubMed.15385831.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15385831.s5.e0" e2="DDI-PubMed.15385831.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15385831.s5.e1" e2="DDI-PubMed.15385831.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15385831.s5.e1" e2="DDI-PubMed.15385831.s5.e2" /></sentence><sentence text=" Serial blood and urine samples were collected for 48 hours, and pharmacokinetic parameters were derived" /><sentence text=" Total clearances of R-(-)- and S-(+)-mexiletine were 42% and 63% higher in smokers compared with nonsmokers (P &lt; 0"><entity charOffset="21-48" id="DDI-PubMed.15385831.s7.e0" text="R-(-)- and S-(+)-mexiletine" /></sentence><sentence text="05)" /><sentence text=" This observation is in agreement with increased clearance of mexiletine under conditions of increased CYP1A2 activity"><entity charOffset="62-72" id="DDI-PubMed.15385831.s9.e0" text="mexiletine" /></sentence><sentence text=" On the other hand, ciprofloxacin administration only marginally decreased R-(-)- and S-(+)-mexiletine clearances (2 to 5 L/h; P &lt; 0"><entity charOffset="20-33" id="DDI-PubMed.15385831.s10.e0" text="ciprofloxacin" /></sentence><sentence text="05) secondary to a decrease in mexiletine nonrenal clearance"><entity charOffset="31-41" id="DDI-PubMed.15385831.s11.e0" text="mexiletine" /></sentence><sentence text=" In conclusion, the increase in mexiletine nonrenal clearance in smokers and its decrease during the combined administration of ciprofloxacin confirm the role of CYP1A2 in the overall clearance of the drug"><entity charOffset="32-42" id="DDI-PubMed.15385831.s12.e0" text="mexiletine" /><entity charOffset="128-141" id="DDI-PubMed.15385831.s12.e1" text="ciprofloxacin" /><pair ddi="false" e1="DDI-PubMed.15385831.s12.e0" e2="DDI-PubMed.15385831.s12.e0" /><pair ddi="false" e1="DDI-PubMed.15385831.s12.e0" e2="DDI-PubMed.15385831.s12.e1" /></sentence><sentence text=" Nevertheless, results obtained in this study suggest that no major drug interaction is to be expected during the concomitant administration of ciprofloxacin and mexiletine in patients"><entity charOffset="144-157" id="DDI-PubMed.15385831.s13.e0" text="ciprofloxacin" /><entity charOffset="162-172" id="DDI-PubMed.15385831.s13.e1" text="mexiletine" /><pair ddi="false" e1="DDI-PubMed.15385831.s13.e0" e2="DDI-PubMed.15385831.s13.e0" /><pair ddi="false" e1="DDI-PubMed.15385831.s13.e0" e2="DDI-PubMed.15385831.s13.e1" /></sentence><sentence text="" /></document>